Abstract
A total of 521 unique clinical isolates from cancer patients with primarily (>90%) bloodstream infections were tested for susceptibility to ceftazidime-avibactam and comparators using broth microdilution methods. Ceftazidime-avibactam inhibited 97.8% of all Enterobacteriaceae (n = 321) at the susceptibility breakpoint of ≥8/4 μg/ml (there were 7 nonsusceptible strains). It was also active against Pseudomonas aeruginosa (91.7% isolates susceptible, n = 121), including many isolates not susceptible to meropenem, cefepime, ceftazidime, piperacillin-tazobactam, or other comparators.
Original language | English (US) |
---|---|
Article number | e02106-16 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 61 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2017 |
Keywords
- Avibactam
- Cancer patients
- Ceftazidime
- Clinical isolates
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases